Study of antitumor activity of antibodies to TNF-α on Walker carcinosarcoma model.

The effect of release-active antibodies to TNF-α (Artrofoon) on the development of Walker carcinosarcoma 256 was studied in Wistar rats. Intragastric dose of this drug significantly inhibited the growth of tumor node (55% inhibition of tumor growth), but less effectively than the reference drug cyclophosphamide (80%). The studied drug significantly prolonged animal' lifespan (+97%) and its efficiency in this respect was comparable to that of cyclophosphamide (+96%).

Experimental study on the efficacy of the drug Brizantin in the model of nicotine dependence.

We estimated the efficacy of Brizantin preparation in suppressing nicotine dependence in rats. It was shown that nicotine-dependent rats in the situation of choice between the chamber with smoke or the chamber with food more frequently entered the chamber with tobacco smoke and stayed there longer. The rats that received Brizantin demonstrated significantly fewer visits to the chamber with smoke and spent there less time. Reduced locomotor activity and orientation and exploratory behavior in rats against the background of Brizantin administration also suggest reduced motivation for smoke inhalation. Thus, Brizantin effectively diminished nicotine dependence in rats in the model of nicotine addiction.

Study of hypoglycemic activity of Subetta and rosiglitazone on the model of streptozotocin-induced diabetes mellitus in rats.

Antidiabetic activity of Subetta was revealed on the model of streptozotocin-induced diabetes mellitus in rats. Intragastric administration of this preparation in a dose of 5 ml/kg for 50 days reduced blood glucose levels, urine levels of glucose and ketone bodies, restored glucose tolerance in the oral glucose test, improved general condition and increased the survival rate of animals. The effectiveness of the drug was not inferior to that of rosiglitazone (8 mg/kg).

Experimental study of the effects of Dietressa, a new weight-reducing drug.

The capacity of a new drug containing ultra-low doses of antibodies to cannabinoid receptor type 1 (Dietressa) to reduce body weight gain in mice on a high-calorie diet was evaluated, possible mechanisms of drug action were analyzed, and its safety (abuse potential in the reaction of self-stimulation) was evaluated. Dietressa was not inferior to sibutramine in reducing body weight gain in mice and exhibited no abuse potential.

Anxiolytic activity of tenoten and diazepam depends on conditions in Vogel conflict test.

We compared two modifications of Vogel conflict test and assessed anxyolitic activity of two drugs: diazepam (benzodiazepine anxiolitic) and tenoten (ultra-low doses of antibodies to S-100 protein) in both modifications of the test. It was found that the intensity of anxiolitic effect of the drugs depends on the conditions of Vogel test.

Effects of Impaza on sexual behavior in different experimental models.

Experiments on different models for sexual behavior (seasonal and age-related inhibition of sexual function, animals with initially reduced sexual function) showed that ultra-low doses of anti-NO-synthase antibodies (Impaza) stimulate sexual motivation and copulative behavior in rats. The effects of the drug on different aspects of sexual behavior depend on the chosen model.

Study of efficiency of therapeutic and preventive anaferon (pediatric formulation) in mice with influenza infection.

Therapeutic and preventive treatment of mice intranasally infected with a lethal dose of A/Aichi/2/68 (H3N2) influenza virus with anaferon (pediatric formulation) demonstrated an antiviral effect of the drug (increased percent of survivors and prolonged lifespan).

A randomized, open-label, comparative, 6-month trial of oral ultra-low doses of antibodies to tumor necrosis factor-alpha and diclofenac in rheumatoid arthritis.

Artrofoon (oral ultra-low doses of antibodies to TNF-alpha is a novel drug approved by the Russian Ministry of Health for the treatment of rheumatoid arthritis (RA). The aim of this study was to assess clinical efficacy and safety of artrofoon in RA compared with diclofenac. In a 6-month, randomized, open-label, comparative trial, 60 patients with active RA (eight men and 52 women aged 23 to 62, mean disease duration 10 years) received artrofoon (8 tablets daily, n = 30) or diclofenac (100 mg daily, n = 30). RA signs and symptoms as well as serum levels of inflammatory markers were evaluated before treatment and at months 1, 3 and 6. Most patients in the artrofoon group showed a 20% improvement in major RA symptoms by the end of the study. The clinical effect rose gradually reaching maximum at month 6. In the artrofoon group, 57% of the patients achieved an American College of Rheumatology (ACR) 20% criteria (ACR20) by month 6 versus 20% of those receiving diclofenac. In some patients in the artrofoon arm, serum proinflammatory cytokine levels significantly decreased (> or = 25% reduction). Diclofenac produced a less pronounced clinical effect, and no changes in cytokine profile. Unlike conventional nonsteroidal anti-inflammatory drugs, artrofoon produced no adverse effects and the overall tolerability and safety were excellent. A half-dose treatment with artrofoon (4 tablets daily) was able to sustain clinical improvements over a 6-month follow-up period. To conclude, artrofoon is a safe and effective treatment for rheumatoid arthritis that acts by influencing the inflammatory process.

Effects of chronic treatment with the eNOS stimulator Impaza on penis length and sexual behaviors in rats with a high baseline of sexual activity.

Endothelial nitric oxide synthase (eNOS) has an important role in erection, and it also affects aspects of sexual behavior. In this experiment, we determined whether a compound enhancing the activity of eNOS, Impaza, could stimulate any aspect of sexual behavior and increase penis length in rats with a high baseline of sexual activity. For comparison, the PDE5 inhibitor sildenafil was included. Male rats were orally treated with Impaza or sildenafil for 28 days. Impaza (3 ml kg(-1)) was given daily while sildenafil (3 mg kg(-1)) was given twice weekly. Tests for sexual incentive motivation and copulatory behavior were performed just before drug treatment and at days 7, 14 and 28 of treatment. In addition, the length of the protruding penis at mount, intromission and ejaculation was measured. Impaza but not sildenafil increased penis length at mount after 14 and 28 days of treatment. The compounds failed to modify sexual incentive motivation or copulatory behavior. It is suggested that Impaza enhanced intracavernous pressure, as such a pressure increase is the most likely explanation for enhanced penis length at mount. This effect, together with an absence of motivational actions, suggests that Impaza may be the most valuable treatment for erectile dysfunction.

Study of bipathic effect of haloperidol.

Parallel treatment with haloperidol and ultralow-dose haloperidol significantly increased the psychotropic neuroleptic effect of traditional doses of the drug under conditions of preliminary of simultaneous administration, which attests to a bipathic effect of this preparation. Combination of ultralow and therapeutic doses of haloperidol significantly reduced its cataleptogenic side effect.

Study of the correlation between clinical efficiency of impaza and serum ADMA level.

Correlation between superlow-dose antibodies to endothelial NO synthase (Impaza) and serum level of ADMA was evaluated in a double blind placebo-controlled study. The reduction of ADMA in patients with erectile dysfunction after impaza treatment was paralleled by improvement of clinical symptoms. No clear-cut correlation between ADMA level and impaza effect was detected.

Anxiolytic and antidepressant characteristics of impaza.

Antibodies to endothelial NO synthase in ultralow doses exhibited anxiolytic and antidepressant effects and their efficiency after single and course treatment is not inferior to that of amitriptyline and diazepam. The psychotropic activity of ultralow-dose antibodies to endothelial NO-synthase is presumably one of important mechanisms of their efficiency in the treatment of erectile dysfunction.

Experimental and clinical study of the effect of artrofoon on proinflammatory cytokine production.

The effect of Artrofoon on the production of proinflammatory cytokines was evaluated in experiments on mice with collagen-induced arthritis and in a clinical study on patients with rheumatoid arthritis. Artrofoon produced an antiinflammatory effect on animals with collagen-induced arthritis and reduced clinical signs of inflammation in patients with rheumatoid arthritis. These changes were accompanied by a significant decrease in the production of tumor necrosis factor-alpha and interleukin-1beta.

Comparative study of pharmacological activity of afala on the model of hormone-induced prostatitis in rats.

Afala (ultralow-dose antibodies to prostate-specific antigen) injected for 60 days to rats with hormone-induced prostatitis caused by sulpiride prevented the development of prostatic hyperplasia and reduced the severity of histological changes. The effect of Afala was superior to that of the reference drug (Serenoa repens extract).

Study of antidiabetic activity of a new ultralow-dose antibody preparation on the model of streptozotocin diabetes in rats.

Antidiabetic activity of a new ultralow-dose preparation of antibodies to insulin receptor beta-subunit was revealed on the model of streptozotocin diabetes in rats: treatment with this preparation in a daily dose of 2.5 ml/kg (for 50 days through a gastric tube) normalized blood glucose level, restored glucose tolerance in the oral glucose test and body weight gain, and improved animal survival. By its hypoglycemic activity and effect on glucose tolerance the preparation was not inferior to classical drugs for the treatment of types 1 and 2 diabetes mellitus insulin (12 U/kg) and glybenclamide (8 mg/kg).

Study of bipathic effect of phenazepam.

Phenazepam in ultralow doses significantly potentiated anxiolytic and anticonvulsant effects of therapeutic doses of the same drug both after preliminary or simultaneous administration, which attests to bipathic action of phenazepam. The combination of ultralow and therapeutic doses of phenazepam prevented the development of its specific myorelaxant and sedative side effects.

Comparison of the cardioprotective effects of cardos and losartan in rats with experimental chronic cardiac insufficiency.

Cardioprotective effect of cardos was revealed on rat model of experimental cardiac insufficiency induced by injectionof isoproterenol. Cardos improved exercise tolerance, cardiac output, and stroke volume. Cardos administered for 28 days was no less effective than losartan.